Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,123
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
ABB, the world's largest maker of power grids, reported third-quarter profit fell by 12% as a slowdown in its big transmission power business continued to bite, but results beat expectations.
More Top Equities Stories Of The Day
Asian Shares Gain, Led By Japan
FTSE 100 Climbs As Oil Stocks Advance
Tablets Again Drive Verizon's Subscriber Growth
Stifel Financial to Hire Two Former Merrill Lynch Advisers
Third Point Wants Amgen to Explore Separation -- Update
U.S. Stocks Gain, but IBM Weighs on Dow
U.S. Hot Stocks: Hot Stocks to Watch
U.S. Hot Stocks: Hot Stocks to Watch
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 183078 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist